Researchers Develop Minimally Invasive Skin Cancer Monitoring Platform
This skin cancer monitoring approach integrates a minimally invasive microneedle platform with a sensitive, single-molecule detection method.
Category: Melanoma
Melanoma
Latest
Melanoma
Latest
Proscia’s AI Selected for Skin Pathology
Unilabs and Proscia have announced that the diagnostic group has chosen Proscia's DermAI skin pathology solution.
Melanoma
Latest
Multicancer Blood Test, Combined with Imaging, Shows Promise as Screen for Cancer
The blood test followed by PET-CT imaging was 99.6% specific for cancer.
New Liquid Biopsy Blood Test Improves Breast Cancer Diagnostics
The TARDIS test could help avoid unnecessary surgeries and enable physicians to continuously monitor cancer.
Read More
Liquid Biopsies Guide Improved Cancer Treatment
Monitoring cancer therapy in real time enables physicians to make smarter treatment decisions.
Read More
Study Supports Tumor-Informed Blood Test as a Predictor of Cancer Survival
Study results support use of the blood test as a surrogate endpoint in clinical trials to assess the effectiveness of immune checkpoint inhibitors.
Read More
January 2019 Product Spotlight: 2019 Emerging Technologies Showcase
Nano-Signature Discovery Could Revolutionize Cancer Diagnosis A quick and easy test to...
Read MoreMyriad’s MyPath Melanoma Test Gets Local Coverage Determination
The test will help patients receive a definitive diagnosis for suspicious skin lesion biopsies.
Read More
Myriad Supports New Guidelines Recommending Genetic Testing for Those with Breast Cancer
Study data demonstrate that about half of patients have clinically actionable mutations that are being missed.
Read More
Lymph Node Analysis Could Improve Melanoma Treatment Options
Studies are demonstrating the potential of the Parsortix system to enhance laboratory efficiency, reduce costs, support medical decisionmaking, and improve patient care.
Read More
Qiagen Expands NGS Portfolio with Oncology and Immunooncology Panels
The research panels can be performed using Qiagen’s GeneReader NGS system and other platforms, providing deep analysis of disease-related genomic mutations.
Read More
Protagen and German National Center for Tumor Diseases, Heidelberg, to Investigate Immunocompetence of Cancer Patients
Protagen has extended its collaboration with the National Center for Tumor Diseases, Heidelberg, to investigate the immunocompetence of urothelial cancer patients receiving immunotherapy.
Read MoreImmunotherapy Effective against Hereditary Melanoma
Almost two-thirds of the patients with CDKN2A mutations responded with tumors that shrank, and for a third of the patients the tumors disappeared completely.
Read More
Collaborators Aim to Improve Therapy Decisions in Immunooncology
The partners will apply deep machine learning to develop biomarker models for relevant treatment-associated endpoints such as immune-related adverse events, clinical response, or survival.
Read More
Asuragen Expands Oncology Portfolio
The panel accurately and sensitively detects more than 1,600 variants of clinical significance.
Read More
Bio-Rad Launches Anti-Idiotypic Antibodies Targeting Pembrolizumab and Nivolumab
Anti-idiotypic antibodies will enable monitoring of for pembrolizumab and nivolumab levels in cancer patients undergoing treatment.
Read More
Liquid Biopsy Scores Immunotherapy Effectiveness
Circulating tumor DNA is a reliable biomarker of tumor progression following immunotherapy treatment.
Read More
Protagen, Gustave Roussy Partner on Risk Profiling of Cancer Patients
Protagen and Gustave Roussy will partner to utilize Protagen’s SeroTag technology to help identify biomarkers that predict and monitor immune-related adverse events in cancer patients treated with checkpoint inhibitors.
Read More